ERBB2 and neoplasm: The distribution according to the primary tumor phenotypes was as follows: HR-positive/HER2-negative 61.4% (n = 336), HR-negative/HER2-negative (triple-negative) 14.5% (n = 79), HER2-positive 24.1% (n = 132).